Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

No studies are availabe for Rac-Amido-TH-naphthyridin (CAS No. 1050477-27-4). According to expert opinion a (weaker) pharmacological action of the compound can be assumed due to the structural similarity to the active pharmaceutical ingredient (API; CAS No. 1050477-31-0). In addition results of in vitro assays reveal that Rac-Amido-TH-naphthyridin acts as a non-steroidal mineralocorticoid receptor (MR) antagonist whereas the IC50 -value is 3 -times higher compared to the corresponding value of the API. As the major findings of the toxicological studies with the API were considered to be related to its pharmacological action, a similar tolerability of the precursor is suggested.

The acute oral toxicity of the API was determined to be: LD50 cut-off value = 300 mg/kg bw in rats according to OECD TG 423. Thus a classification in Category 3 is warranted.

Justification for classification or non-classification

According to the corresponding active pharmaceutical ingredient (CAS No. 1050477-31-0) the substance is classified in Category 3 (oral route).